Coal India advances Technology-led Diversification Across Energy & Minerals (See 'Corp Brief') Digital India RISC-V Grand Challenge under C2S Programme awarded to 3 teams (See 'Corp Brief') IBC - Arrangement of funds to enable corporate debtor to clear its liabilities, coupled with transfer of funds from cooperative bank loan account of applicant directly to bank, is not valid loan disbursement under IBC: NCLT (See 'Legal Desk') Vaishnaw highlights ISM 2.0, indigenous design, manufacturing, talent and India's emergence (See 'Corp Brief') SEBI - SEBI, acting as statutory market regulator, is duty-bound to issue a reasoned, speaking order when a decision carries serious civil consequences for acquirer, target company & investors: SAT (See 'Legal Desk') An unsuccessful 'success fee' litigation (See CORP EINSICHT) Centre commemorates World Patient Safety Day 2026 at NIHFW (See 'Corp Brief') BIMSTEC Energy Centre organises 5-Day Capacity Building Programme (See 'Corp Brief') Scindia inaugurates Renovated Guna Head Post Office in MP (See 'Corp Brief') SEBI - Where material on record discloses need for deeper scrutiny, re-appreciation, review or reconsideration of evidence, leave ought to be granted & the appeal should thereafter be decided on merits: HC (See 'Legal Desk') CCI nod for acquisition of equity of Great White Global by ISAF III Onshore Fund (See 'Corp Brief') From Ink and Ledger to Cloud and Cipher: The Bankers' Books Evidence Act, 2026 - A Critical Appraisal of India's Digital Evidentiary Revolution (See CORP EINSICHT) A&C Act - Question whether particular claim is covered by, or falls outside excepted matters clause of works contract is matter squarely within competence of Arbitral Tribunal u/s 16 of Arbitration and Conciliation Act: SC (See 'Legal Desk') CCI approves acquisition of addl share in Azure Power Global by OMERS Infra (See 'Corp Brief') Beneficiaries express confidence in government policies for e-mobility (See 'Corp Brief') Competition Act - Regulatory decisions taken in exercise of statutory powers not subject to review by CCI; authority concerned is not amenable to scrutiny u/s 4 of Competition Act: CCI (See 'Legal Desk') Semicon 2.0 mission to focus semiconductor design & fabrication; to create 1 lakh jobs (See 'Corp Brief') NLMC to host investor meets ahead of RINL land e-auction (See 'Corp Brief') SEBI - Penalty order under SEBI (PFUTP) Regulations unsustainable where foundational findings regarding volume of manually deleted orders & manipulative intent are perverse & contrary to the record: SAT (See 'Legal Desk') Govt reviews Use of Steel from Ship Recycling to Boost Steel Manufacturing (See 'Corp Brief') Inaugural PDUNASS–GNLU Executive Program on Labour Law concludes at Gandhinagar (See 'Corp Brief') Capital Market - Release of escrow amount maintained for buyback does not bar separate inquiry into alleged fraud under PFUTP Regulations: SC (See 'Legal Desk')

Print

'Cohort Connect 2025' to be India's Largest evidence-based study on Genetic

Published: Nov 14, 2025

By TIOLCorplaws News Service

NEW DELHI, NOV 14, 2025: ON the eve of World Diabetes Day tomorrow, Union Minister of State (Independent Charge) for Science & Technology, MoS PMO, Personnel, Public Grievances, Pensions, Atomic Energy and Space, Dr Jitendra Singh today launched "Phenome National Conclave on Longitudinal Cohort Studies: Cohort Connect 2025", at CSIR–IMMT, here.

Cohort Connect is said to be India's largest evidence-based study on Genetic, Lifestyle and Environmental drivers of Disease.

Delivering the inaugural address, Dr. Jitendra Singh said that the discussion taking place a day before World Diabetes Day carries special relevance, as metabolic disorders like diabetes are rapidly emerging as a major national health challenge. He emphasised that diabetes today represents not just a clinical condition but a complete spectrum of vascular, neurological, and renal complications, making scientific research in this domain critical for national planning.

On the eve of World Diabetes Day, Dr. Jitendra Singh said that India's fight against diabetes and other rising metabolic disorders requires Indian data for Indian solutions, supported by long-term scientific evidence.

The Minister recalled that metabolic disorders, especially Type-2 diabetes, once considered region-specific, have now spread across the country due to lifestyle transitions and changing environmental patterns, turning what was earlier a South India–predominant condition into a pan-India challenge. He emphasized that India continues to deal simultaneously with both communicable and non-communicable diseases, and the reciprocal link between diabetes and infections such as tuberculosis requires integrated policy responses rather than compartmentalised programmes.

Dr. Jitendra Singh underscored that India's phenotypic uniqueness has been acknowledged for decades, but could never be scientifically validated due to limited genomic and epidemiological infrastructure. With initiatives like CSIR-led Phenome India and the large-scale longitudinal cohort studies being undertaken, India now can accurately capture how genetics, environment, diet, and lifestyle shape disease predisposition in Indian populations.

The Minister noted that even Indians living abroad for generations show distinctive susceptibility to metabolic disorders, highlighting the fundamental role of inherited traits.

The Minister shared clinical and historical insights illustrating how global medical understanding has evolved- from pre-insulin starvation-era diabetes management to today's genetic therapies, and urged caution in adopting new drugs and technologies without long-term evidence suited to Indian populations. He recalled that refined oils were once promoted as heart-friendly, only to be later linked with rising coronary artery disease in India, reinforcing the need for rigorous, long-term, India-specific studies before public health recommendations are made.

Highlighting Government initiatives, Dr. Jitendra Singh said that both CSIR and the Department of Biotechnology are working actively on human genome sequencing, with nearly 10,000 human genomes already sequenced and the target of one million genomes progressing rapidly. He also mentioned India's first successful haemophilia trial with indigenously developed Factor VIII, underscoring India's rising capabilities in advanced biomedical research.

Dr Jitendra Singh added that the Government is simultaneously working on vaccines for diseases like dengue, malaria, and tuberculosis, while AI-driven diagnostics, digital health platforms and quantum-enabled solutions are increasingly becoming part of India's medical ecosystem.

The Minister reiterated that with 70% of India's population below 40, prevention must be the central pillar of India's future health strategy. A robust cohort study ecosystem, he said, will generate actionable datasets for preventive, prophylactic and therapeutic pathways tailored to Indian needs. He appreciated CSIR institutions, project investigators, and private-sector partners for creating a platform that integrates science, evidence creation, and translational application through MoUs and venture collaborations.

Dr. Jitendra Singh concluded by stating that India's health status in 2047 will define the vision of Viksit Bharat, and scientific initiatives like Phenome India and Cohort Connect 2025 would serve as foundational pillars in achieving that goal. Citing Hippocrates, he said that even without tools or medicines, a doctor's knowledge can heal; similarly, India's collective scientific wisdom will drive its health transformation in the coming decades.

The inaugural session was attended by Dr. Ramanuj Narayan, Director, CSIR–IMMT, Dr. Maiti (CSIR–IGIB), Dr.Kooti, Dr. Debashish, senior scientists, project investigators, and media representatives. They briefed the press on the objectives and emerging insights from the Phenome India longitudinal cohort, along with the agenda of the upcoming National Conclave on Longitudinal Cohort Studies: Cohort Connect 2025, scheduled to be held at CSIR–IMMT, Bhubaneswar.

TIOL CORP SEARCH

TIOL GROUP WEBSITES

taxindiaonline
taxindiainternational
TKF
TIOLawards
A TIOL Website. Copyright © 2025 TIOLcorplaws.com All rights reserved.